Neurogen cuts jobs

Share this article:
Neurogen said it laid off 70 workers and is taking a charge of about $1.5 million in the first quarter of 2008 to pay severence benefits and other charges.

The move is part of a restructuring to focus resources on advancing its pipeline of insomnia and other compounds including Phase II candidate aplindore for Parkinson's disease and restless legs syndrome.

Neurogen reported a net loss of $40 million for the nine months ended Sept. 30, 2007.
The job cut announcement came just days after Stephen Davis, a lawyer, became president and CEO. Davis succeeds William Koster, who has retired, but remains a director.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.